Valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy: The design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial

For the VANISH trial investigators and executive committee

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Fingerprint Dive into the research topics of 'Valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy: The design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial'. Together they form a unique fingerprint.

Medicine & Life Sciences